innerbuddies gut microbiome testing

Gut Microbiome and MASLD/NAFLD Fibrosis Risk: What the Research Shows

The gut microbiome is increasingly recognized as a key player in MASLD/NAFLD progression—especially when it comes to the risk of liver fibrosis. While fatty liver can develop silently, not everyone follows the same path: microbial composition and function may help explain why some people transition toward inflammatory injury and scar formation more rapidly than others.

Research suggests that gut microbial imbalance (often reduced microbial diversity and shifts in bacterial groups) can promote liver inflammation through multiple pathways. These include increased gut permeability (“leaky gut”), which allows microbial products such as lipopolysaccharide to reach the liver and amplify immune signaling; altered bile acid metabolism that can affect hepatic fat handling and inflammation; and changes in short-chain fatty acid production that influence gut barrier integrity and metabolic regulation. Together, these mechanisms can feed the inflammatory cascade that underlies fibrogenesis.

The good news is that this biology also points to measurable signals and opportunities. Studies are exploring gut-derived microbial patterns and metabolites as potential biomarkers for identifying higher fibrosis risk earlier—along with gut-targeted strategies such as dietary fiber optimization, targeted prebiotics/probiotics, and microbiome-supportive lifestyle changes. As the evidence grows, understanding your gut microbiome may become a practical way to better assess risk and potentially slow progression toward advanced fibrosis.

Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Fibrosis-risk context

MASLD (formerly NAFLD) is a chronic liver condition whose risk of fibrosis is strongly influenced by the gut microbiome. Dysbiosis with reduced beneficial diversity and more pro-inflammatory taxa can disrupt the gut barrier, allowing lipopolysaccharide (LPS) and other microbial products to reach the liver and activate innate immune signaling (including Toll-like receptors) that drives hepatic stellate cell activation and fibrogenesis. Changes in bile acid metabolism and reduced protective metabolites like short-chain fatty acids (SCFAs) further promote inflammation and metabolic stress, contributing to fibrosis progression.

  • Loss of key SCFA-producing and mucus-associated taxa (Akkermansia muciniphila; Faecalibacterium prausnitzii; Roseburia spp.; Coprococcus spp.; Anaerostipes spp.; Butyrivibrio spp.; Ruminococcus bromii) reduces butyrate-propionate production, weakening gut barrier and promoting hepatic inflammation and fibrogenesis.
  • Increase of pro-inflammatory, dysbiosis-associated taxa (Enterobacteriaceae such as Escherichia/Shigella; Streptococcus; Bacteroides fragilis group; Ruminococcus gnavus; Fusobacterium; Veillonella) drives lipopolysaccharide translocation and Toll-like receptor–mediated cytokine signaling that activates hepatic stellate cells.
  • Dysbiosis perturbs bile acid metabolism and signaling (FXR and related pathways) via altered bile-acid–modifying microbes, shifting pools toward greater liver injury risk.
  • Functional microbiome shift with reduced SCFA biosynthesis pathways and related anti-inflammatory outputs increases oxidative stress and inflammation, favoring extracellular matrix deposition.
  • Microbiome-based risk stratification combines diversity metrics, key taxa patterns (loss of protective taxa; gain of pro-inflammatory taxa), and functional signals with inflammatory/metabolic markers to identify MASLD patients at higher fibrosis risk.
  • Gut-focused interventions—fiber-rich, plant-diverse diets to boost SCFA producers, metabolic risk optimization, and carefully selected prebiotics/probiotics—are being explored to slow MASLD progression.
  • Clinical testing of the microbiome offers actionable insight into gut barrier integrity and inflammatory pressure, complementing traditional biomarkers to guide personalized prevention strategies.
Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

MASLD / NAFLD spectrum

MASLD (formerly called NAFLD) is a chronic liver condition driven by metabolic dysfunction, and a key clinical concern is progression from simple steatosis to inflammation, fibrosis, and—ultimately—cirrhosis. In recent years, the gut microbiome has emerged as an important contributor to this fibrosis risk. Research suggests that altered microbial composition (often described as reduced beneficial diversity and an overgrowth of pro-inflammatory taxa) can promote intestinal permeability, enabling bacterial products such as lipopolysaccharide to reach the liver and amplify immune-driven inflammation. This inflammatory signaling can accelerate fibrogenesis through pathways involving innate immunity (including Toll-like receptor signaling), cytokine production, and downstream activation of hepatic stellate cells.

Multiple microbiome-associated mechanisms link gut changes to MASLD/NAFLD severity. Dysbiosis may shift microbial fermentation patterns and bile acid metabolism, affecting metabolic signaling (e.g., via farnesoid X receptor and other bile-acid–sensing pathways) that normally helps maintain metabolic homeostasis and reduce hepatic injury. In parallel, microbial metabolites—such as short-chain fatty acids (SCFAs) that support gut barrier integrity and anti-inflammatory tone—may be reduced, while other metabolites may increase oxidative stress or inflammatory signaling. Together, these changes help explain why certain microbiome profiles are repeatedly associated with more advanced fibrosis, although results vary across populations and study designs.

Because microbiome patterns reflect both liver disease biology and host factors (diet, insulin resistance, medications), they are being explored as potential biomarkers to identify patients at higher risk for progression. The most promising approaches look at combinations of microbial diversity measures, specific taxa, functional microbial pathways (not just “who’s there”), and circulating markers of inflammation or metabolic dysregulation. Alongside diagnostics, gut-focused strategies—dietary interventions rich in fiber and diverse plant foods (to support SCFA-producing communities), targeted management of metabolic risk, and in some cases carefully selected prebiotic/probiotic or microbiome-modulating therapies—are being investigated for their ability to reduce inflammatory load and slow fibrosis progression. While no single microbial marker is yet definitive for clinical decision-making, the overall evidence supports the gut microbiome as a meaningful modulator of MASLD/NAFLD fibrosis risk and a potential target for future prevention and precision-risk stratification.

  • Fatigue and low energy
  • Right upper abdominal discomfort or fullness
  • Unexplained weight loss or reduced appetite
  • Abdominal bloating and discomfort
  • Jaundice (yellowing of the skin/eyes)
  • Easy bruising or bleeding (suggesting impaired liver function)
  • Swelling in the legs or abdomen (edema/ascites)
  • Itching (cholestasis-related pruritus)
Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Fibrosis-risk context

This content is most relevant for people who have (or are being evaluated for) MASLD/NAFLD and want to understand why some patients are more likely to progress from fat in the liver to inflammation and fibrosis. It’s especially useful for patients and clinicians thinking about “fibrosis-risk context,” where the goal is identifying higher-risk individuals earlier rather than waiting for advanced liver damage. It also fits those interested in emerging gut microbiome–based explanations and potential biomarkers that reflect gut-driven inflammatory signaling.

It’s also relevant for individuals experiencing symptoms that may suggest worsening liver function or more advanced disease—such as fatigue, right upper abdominal discomfort/fullness, abdominal bloating, unexplained weight loss or reduced appetite, and jaundice. Because gut microbiome changes are linked to intestinal barrier dysfunction and immune activation, these symptoms can overlap with the inflammatory burden that may contribute to fibrosis progression, making the microbiome a particularly relevant area of focus. Additionally, it may apply to people noticing easy bruising/bleeding and itching, which can indicate impaired liver function and cholestasis-related effects.

Finally, this is relevant for patients with metabolic risk factors (e.g., insulin resistance, obesity, dyslipidemia) who want a clearer picture of how diet, bile acid metabolism, and gut microbial metabolites may influence liver injury. It’s also appropriate for readers considering gut-targeted prevention strategies—like higher-fiber, plant-forward eating patterns that support beneficial SCFA-producing microbes, and for those discussing future or investigational prebiotic/probiotic or microbiome-modulating therapies. If you’re looking for a precision-risk perspective—combining microbiome profiles with inflammation/metabolic markers—this content aligns with that direction.

MASLD (formerly NAFLD) is extremely common worldwide and is now considered one of the leading chronic liver diseases. Depending on the population and diagnostic method, estimated prevalence is roughly ~25% of adults globally, with higher rates in people with obesity and type 2 diabetes. In practical terms, this means that in many countries about one in four adults may have fat accumulation in the liver related to metabolic dysfunction, making fibrosis-risk assessment a major public health need.

Regarding progression risk and fibrosis, a substantial minority of people with MASLD develop more advanced disease rather than remaining in early steatosis alone. Across studies, about ~10–20% of individuals with MASLD are estimated to have advanced fibrosis (often corresponding to stages associated with a significantly higher risk of cirrhosis and liver-related outcomes). Clinically, this fibrosis progression is the concern described in the microbiome–fibrosis context: gut dysbiosis may increase intestinal permeability and pro-inflammatory signaling that can accelerate fibrogenesis in the liver.

Symptoms often reflect more advanced involvement of liver function and/or inflammation, but many people with MASLD—especially early stages—have few or nonspecific complaints. When present, symptoms such as fatigue, right upper abdominal discomfort/fullness, abdominal bloating, and later signs like jaundice, easy bruising/bleeding, leg/abdominal swelling (ascites/edema), and itching are more suggestive of clinically significant liver impairment. Because symptom severity varies widely and early disease can be asymptomatic, prevalence figures usually come from screening cohorts rather than symptom-based estimates, underscoring why biomarker approaches (including microbiome-associated risk stratification) are being explored to identify the subset most likely to progress to fibrosis.

Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and MASLD/NAFLD Fibrosis Risk: What the Research Shows

MASLD (formerly NAFLD) is driven by metabolic dysfunction, and gut microbiome changes are increasingly recognized as a contributor to fibrosis-risk progression. In many patients, dysbiosis is characterized by reduced beneficial microbial diversity and an overgrowth of pro-inflammatory microbes. This can weaken intestinal barrier integrity, allowing bacterial components such as lipopolysaccharide (LPS) to translocate to the liver and amplify immune-driven inflammation—an important accelerator of fibrogenesis through innate immune pathways (including Toll-like receptor signaling) and cytokine release that activates hepatic stellate cells.

Beyond barrier effects, the microbiome influences bile acid metabolism and metabolic signaling, which can shape susceptibility to liver injury. Dysbiosis may alter microbial fermentation patterns and shift bile acid pools, affecting receptors such as farnesoid X receptor (FXR) and other bile-acid–sensing pathways that normally help maintain metabolic homeostasis and limit hepatic inflammation. At the same time, protective metabolites like short-chain fatty acids (SCFAs)—which support gut barrier function and anti-inflammatory tone—may be reduced, while other microbial products can increase oxidative stress and inflammatory signaling, together creating a biochemical environment that favors worsening fibrosis.

Because microbial patterns reflect both liver disease biology and host factors (diet, insulin resistance, medications), microbiome signatures are being studied as potential biomarkers of higher risk for progression. While no single taxon or test is definitive yet, evidence supports combining measures of diversity, specific microbial taxa, functional microbial pathways, and circulating inflammation/metabolic markers to better identify patients likely to develop advanced fibrosis. These links also motivate gut-focused strategies—such as increasing fiber-rich, plant-diverse diets to promote SCFA-producing communities, optimizing metabolic risk, and exploring carefully selected prebiotics/probiotics or microbiome-modulating therapies—to reduce inflammatory load and potentially slow disease progression. Clinically, fibrosis-advancing MASLD can manifest with fatigue, right upper abdominal discomfort, bloating, weight loss, and in more advanced disease signs such as jaundice, easy bruising/bleeding, edema/ascites, and pruritus—symptoms that may correlate with the inflammatory and metabolic disturbances shaped in part by the gut ecosystem.

Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and Fibrosis-risk context

  • Dysbiosis-driven loss of microbial diversity and overgrowth of pro-inflammatory taxa that increase intestinal permeability (“leaky gut”).
  • Barrier disruption enables bacterial products—especially lipopolysaccharide (LPS)—to translocate to the liver, activating innate immune pathways (e.g., Toll-like receptor signaling) and pro-fibrotic cytokine release.
  • Microbiome-mediated bile acid dysregulation alters bile acid pools and signaling through receptors such as FXR, shifting metabolic homeostasis and increasing susceptibility to liver inflammation and injury.
  • Reduced production of protective microbial metabolites (notably short-chain fatty acids, SCFAs) lowers anti-inflammatory tone and impairs gut barrier integrity, indirectly promoting fibrogenesis.
  • Microbial fermentation and metabolite changes can increase oxidative stress and inflammatory signaling, creating an environment that favors hepatic stellate cell activation and extracellular matrix deposition.
  • Microbiome effects on host metabolic signaling (gut-liver axis hormones and pathways related to insulin resistance) amplify metabolic dysfunction that drives MASLD progression and fibrosis risk.
  • Potential microbiome signature changes reflect disease biology and host factors (diet, adiposity, medications), enabling risk stratification but also indicating active pathways that influence progression.

In MASLD, metabolic dysfunction reshapes the gut microbiome, often leading to dysbiosis marked by reduced microbial diversity and an increase in pro-inflammatory species. This shift can weaken intestinal barrier integrity (“leaky gut”), making it easier for bacterial components such as lipopolysaccharide (LPS) to cross into the circulation and reach the liver. Once in the hepatic environment, LPS and other microbial products stimulate innate immune signaling—particularly Toll-like receptor pathways—and drive cytokine release that accelerates fibrogenesis by promoting hepatic stellate cell activation.

Dysbiosis also disrupts gut–liver communication through bile acid metabolism. Microbial communities help transform primary bile acids into secondary bile acids, and changes in this processing can alter bile acid pools and signaling through receptors such as FXR and other bile-acid–sensing pathways. Because these pathways normally support metabolic homeostasis and help limit inflammatory responses, altered bile acid signaling can increase the liver’s susceptibility to injury and amplify the inflammatory tone that favors progression from steatosis toward fibrosis.

In addition, protective microbial metabolites—especially short-chain fatty acids (SCFAs)—may decline when beneficial SCFA-producing organisms are reduced. SCFAs help support the gut barrier and temper inflammation, so lower levels can indirectly increase fibrotic risk. Meanwhile, shifts in microbial fermentation and metabolite production can raise oxidative stress and reinforce inflammatory signaling, further creating a biochemical environment that supports extracellular matrix deposition. Together, these microbiome-driven effects on barrier function, immune activation, bile acid signaling, and metabolic regulation can compound insulin resistance and other metabolic drivers of MASLD, helping explain why certain microbiome patterns are being explored for fibrosis-risk stratification.

Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Microbial patterns summary

In MASLD, dysbiosis commonly shows up as reduced gut microbial diversity alongside an imbalance toward communities associated with higher inflammation. This altered ecosystem can compromise intestinal barrier integrity, making it easier for microbial products—especially lipopolysaccharide (LPS)—to move across the gut barrier and reach the liver. The resulting increase in innate immune activation (including Toll-like receptor signaling) supports a sustained inflammatory environment that promotes hepatic stellate cell activation, a key step in the transition from steatosis toward fibrosis.

Another hallmark pattern involves disrupted gut–liver signaling through bile acid metabolism. Normally, gut microbes convert primary bile acids into secondary forms that help regulate metabolic and inflammatory pathways via bile acid–sensing receptors such as FXR. In dysbiosis, shifts in the composition and function of bile-acid–modifying microbes can change bile acid pool size and signaling tone, weakening protective homeostatic effects and increasing vulnerability to liver injury. This can further interact with metabolic dysfunction, amplifying insulin resistance–related stress and sustaining inflammatory pathways that favor progression.

Dysbiosis in fibrosis-risk MASLD also often reflects a reduced capacity for producing protective microbial metabolites, particularly short-chain fatty acids (SCFAs). When SCFA-producing taxa decline, the gut’s anti-inflammatory and barrier-supporting effects can diminish, allowing additional inflammatory signaling and increasing intestinal permeability. At the same time, functional changes in microbial fermentation and metabolite output may elevate oxidative stress and pro-inflammatory biochemical signals, helping create a microenvironment that supports extracellular matrix deposition and fibrogenesis over time.


Low beneficial taxa

  • Akkermansia muciniphila
  • Faecalibacterium prausnitzii
  • Roseburia spp.
  • Anaerostipes spp.
  • Bifidobacterium spp.
  • Butyrivibrio spp.
  • Ruminococcus bromii
  • Coprococcus spp.


Elevated / overrepresented taxa

  • Enterobacteriaceae (e.g., Escherichia/Shigella)
  • Streptococcus
  • Bacteroides (notably Bacteroides fragilis group)
  • Ruminococcus gnavus group
  • Fusobacterium
  • Proteobacteria (family-level, dysbiosis-associated blooms)
  • Veillonella


Functional pathways involved

  • Short-chain fatty acid (SCFA) biosynthesis and butyrate/propionate production pathways (e.g., via acetyl-CoA fermentation)
  • Bile acid metabolism and microbial bile acid transformation (primary-to-secondary conversion and FXR/TGR5 signaling modulation)
  • Intestinal barrier integrity and mucus layer-support pathways (including mucin utilization and maintenance of tight-junction–supporting metabolites)
  • Lipopolysaccharide (LPS) biosynthesis and membrane component trafficking that drive TLR4/innate immune activation
  • Toll-like receptor (TLR) and innate immune inflammatory signaling (MyD88/TRIF downstream programs triggered by microbial products)
  • Bacterial protein fermentation and branched-chain amino acid (BCFA) catabolism leading to potentially pro-inflammatory metabolites
  • Oxidative stress and redox/fermentation byproduct pathways that increase pro-fibrogenic oxidative microenvironments in the gut–liver axis
  • Microbial dysbiosis-associated lipopolysaccharide/peptidoglycan sensing and downstream hepatic stellate cell activation via pro-inflammatory cytokine signaling


Diversity note

In fibrosis-risk MASLD (formerly NAFLD), a common gut microbiome change is reduced microbial diversity, often accompanied by an imbalance in community composition toward taxa associated with a more pro-inflammatory milieu. This loss of diversity can correlate with a less resilient ecosystem, where protective microbial functions are diminished and inflammatory signals become easier to sustain over time.

Alongside lower diversity, dysbiosis frequently reflects disrupted gut–liver communication that can further worsen the downstream impact of inflammation on fibrosis risk. Shifts in microbial metabolism—particularly in pathways that modify bile acids—may change the balance of microbial functions linked to homeostatic signaling through receptors such as FXR. When beneficial bile-acid–modifying communities decline or their activity is altered, protective regulatory tone can weaken, leaving the liver more vulnerable to injury.

Reduced diversity is also often paired with a decreased capacity to generate anti-inflammatory metabolites such as short-chain fatty acids (SCFAs). When SCFA-producing communities are less abundant, intestinal barrier support and anti-inflammatory signaling tend to fall, which can promote greater intestinal permeability. This environment makes it easier for bacterial components like lipopolysaccharide (LPS) to influence innate immune pathways, reinforcing inflammation that can drive hepatic stellate cell activation and progression from steatosis toward fibrosis.


Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription

Why generic solutions fail

  • Issue with generic solutions

    Generic “one-size-fits-all” gut interventions often fail in fibrosis-risk MASLD because the gut ecosystem isn’t uniformly dysbiotic across patients, and the disease drivers are not purely microbial. In many cases, dysbiosis reflects deeper metabolic dysfunction (insulin resistance, diet composition, medication effects, and weight-related inflammation). If these upstream factors remain unaddressed, the gut microbiome can quickly revert to a pro-inflammatory pattern, so broad measures that do not target the specific drivers of inflammation and barrier disruption tend to show limited or short-lived benefit.

    Another reason generic solutions underperform is that fibrosis-risk progression depends on specific functional disturbances—not just overall “more probiotics” or “eat more fiber.” The microbiome’s impact on LPS translocation, Toll-like-receptor–mediated innate immune activation, and hepatic stellate cell signaling is highly contingent on intestinal barrier integrity and bile acid metabolism. Generic probiotic blends or nonspecific prebiotic additions may not meaningfully restore bile-acid–sensing pathways (e.g., FXR signaling) or increase the right SCFA-producing functional capacity for anti-inflammatory tone, leaving the core immune and metabolic signaling loops still primed for fibrogenesis.

    Finally, many generic approaches ignore the fact that microbial patterns serve as both cause and consequence of liver disease biology, so biomarkers and patient stratification matter. Without tailoring—such as matching dietary fiber diversity and fermentation substrates to an individual’s microbial baseline, considering dysbiosis severity, and integrating metabolic risk management—interventions can fail to reduce endotoxin load, oxidative stress, and pro-inflammatory metabolite signals. The result is that patients may experience symptom-level changes without achieving the gut–liver functional shifts needed to meaningfully slow fibrosis-risk trajectory.

  • Common mistakes

    • Using one-size-fits-all probiotics/prebiotics without assessing each patient’s specific dysbiosis pattern (e.g., diversity loss vs bile-acid–metabolism disruption vs SCFA-producing capacity).
    • Failing to target upstream drivers that keep the microbiome in a pro-inflammatory state (diet composition, insulin resistance, ongoing weight-related inflammation, and medication effects).
    • Assuming “more fiber” automatically restores the specific functional pathways needed for fibrosis-risk MASLD—especially bile-acid conversion and FXR-mediated homeostatic signaling.
    • Relying on generic probiotic blends without ensuring they meaningfully improve intestinal barrier integrity and reduce LPS translocation / Toll-like-receptor activation.
    • Not stratifying by fibrosis-risk biology, so interventions aren’t matched to whether the dominant mechanism is endotoxin-driven innate immune activation, bile-acid signaling tone, or reduced SCFA/anti-inflammatory metabolite production.
    • Optimizing for short-term symptom relief rather than measurable gut–liver functional outcomes (e.g., endotoxin load, bile acid pool/signaling profiles, SCFA availability, oxidative stress markers).
    • Overlooking that microbial patterns are both cause and consequence of liver disease progression—so not pairing gut-directed changes with liver-metabolic management (dietary quality, glycemic control, lifestyle).
    • Ignoring dose/formulation and substrate specificity (e.g., not matching fermentation substrates to the patient’s microbial baseline), leading to rapid microbiome reversion after the intervention.

What to do

  • General support strategies

    Supporting fibrosis-risk in MASLD increasingly centers on reducing gut-derived inflammatory pressure and restoring a healthier microbial ecosystem. Since dysbiosis can weaken intestinal barrier integrity and promote translocation of pro-inflammatory bacterial components such as LPS, strategies that improve barrier function and lower overall immune activation may help slow fibrogenesis. Clinically, this often aligns with diet patterns that increase microbial diversity and encourage beneficial, anti-inflammatory communities (including SCFA-producing taxa), alongside efforts to optimize metabolic drivers that shape the gut–liver axis.

    Dietary fiber and plant diversity are foundational. A gradual shift toward a fiber-rich, whole-food pattern—emphasizing vegetables, legumes, whole grains, nuts, and a variety of micronutrient-dense plants—can raise production of short-chain fatty acids (SCFAs), which support intestinal tight junctions and help maintain an anti-inflammatory tone. For some patients, carefully selected prebiotic approaches (e.g., fermentable fibers) may help selectively feed beneficial microbes, while probiotic or microbiome-modulating therapies may be considered as adjuncts when individualized to the patient’s condition, tolerance, and overall treatment plan.

    Because microbiome signals reflect both disease biology and host factors, combining gut-focused measures with metabolic optimization offers the most consistent framework for supporting lower progression risk. Addressing insulin resistance, reducing weight when appropriate, limiting dietary patterns that worsen metabolic stress, and reviewing medication effects that may influence the microbiome can all contribute to a more favorable gut environment. Over time, clinicians may also incorporate a broader “risk context” by monitoring inflammatory and metabolic markers and—where available—microbiome-related signals, to better identify patients who may benefit most from targeted nutrition and gut-directed interventions.

  • Lifestyle recommendations

    • Adopt a fiber-rich, plant-diverse eating pattern (e.g., vegetables, legumes, whole grains, nuts) to support SCFA-producing gut microbes and improve intestinal barrier function.
    • Limit alcohol and minimize ultra-processed foods and added sugars, which can worsen metabolic dysfunction and promote pro-inflammatory dysbiosis relevant to fibrosis risk.
    • Achieve and maintain weight loss if overweight through calorie control and sustainable dietary changes, since improving insulin resistance lowers progression risk.
    • Engage in regular physical activity (aerobic plus resistance training when feasible) to improve metabolic signaling and reduce inflammatory tone.
    • Use antibiotics and other gut-impacting medications only when clearly indicated, and discuss timing/necessity with a clinician to reduce unnecessary microbiome disruption.
    • Consider clinician-guided prebiotic/probiotic or dietary supplement strategies (e.g., fiber/prebiotics first) rather than self-directed high-dose regimens, aiming to reduce inflammatory load and support gut stability.

  • Nutrition recommendations

    • Follow a fiber-forward, plant-diverse diet (aim for ~25–38 g/day fiber) using legumes, vegetables, berries, whole grains, nuts, and seeds to support SCFA-producing microbes and intestinal barrier integrity.
    • Prioritize minimally processed, whole-food carbohydrates (e.g., oats, barley, brown rice in controlled portions) and reduce refined carbs and added sugars to lower metabolic stress that drives MASLD progression.
    • Increase unsaturated fats (extra-virgin olive oil, avocado, nuts, seeds, fatty fish) while minimizing saturated fat and fried/ultra-processed foods that can worsen dysbiosis and hepatic inflammation.
    • Include prebiotic food sources regularly (e.g., garlic, onions, leeks, asparagus, chicory root/inuin, bananas/plantains when cooled) to selectively feed beneficial taxa and strengthen anti-inflammatory signaling.
    • Reduce alcohol intake or avoid it entirely, and limit sugary beverages (soda, juice, sweetened drinks) to decrease inflammatory load and oxidative stress tied to fibrosis-risk pathways.
    • If needed, target gradual weight loss through caloric moderation and protein adequacy (lean proteins like fish, poultry, tofu/tempeh, Greek yogurt) to improve insulin resistance while preserving lean mass—supporting healthier gut-metabolic signaling.

  • Supplement considerations

    In a fibrosis-risk (MASLD) context, gut-focused supplements are often considered with the goal of improving microbial balance, strengthening intestinal barrier function, and reducing pro-inflammatory signaling that can amplify hepatic injury. Dysbiosis commonly involves reduced beneficial microbial diversity and overgrowth of pro-inflammatory organisms, which may promote gut permeability and allow bacterial products such as lipopolysaccharide (LPS) to drive innate immune activation in the liver (including Toll-like receptor pathways) and accelerate fibrogenesis. Supplement strategies that support a healthier microbial ecosystem—particularly those that increase short-chain fatty acid (SCFA) production—may be appealing because SCFAs can help reinforce the gut barrier and shift immune tone toward less inflammation.

    Bile acid metabolism and metabolic signaling are also influenced by the microbiome, so supplement considerations frequently include approaches that help normalize bile acid pools and receptor signaling (e.g., FXR-related pathways) that support metabolic homeostasis and limit hepatic inflammatory stress. Fiber-related prebiotic supplements (such as inulin- or resistant-starch–type fibers, when tolerated) are commonly used to feed SCFA-producing microbes, while carefully chosen probiotics or synbiotics may be considered to help modulate microbial composition and functional pathways. Because evidence varies by strain, dose, and baseline gut status, it’s generally most prudent to select products with strain-level labeling and clinically relevant formulations rather than relying on broad “high CFU” claims.

    Finally, because host factors (insulin resistance, diet quality, and medication use) strongly shape microbiome patterns and progression risk, supplements are best viewed as adjuncts to metabolic optimization and dietary fiber adequacy. In practice, tolerability matters: some microbiome-modulating supplements can worsen bloating or GI discomfort early on, so gradual titration is often recommended. Monitoring inflammatory and metabolic markers with clinical follow-up can help determine whether a supplement approach is supportive for fibrosis-risk reduction, especially since symptoms tied to advanced MASLD—such as fatigue, right upper abdominal discomfort, edema/ascites, easy bruising, or jaundice—can reflect ongoing inflammatory and hepatic functional changes.

  • Retesting / monitoring note

    For patients in a fibrosis-risk context such as MASLD (formerly NAFLD), retesting is typically considered when there is clinical change, progression on noninvasive liver assessment, or after an intervention intended to modify gut-driven inflammatory and metabolic drivers. Because gut dysbiosis can reflect both disease biology and modifiable host factors (diet quality, insulin resistance, medications), retesting is most informative when it is timed to capture meaningful shifts rather than short-term fluctuations—often after sustained lifestyle or microbiome-targeted changes (e.g., improved fiber intake or carefully selected pre-/probiotic strategies) and once metabolic parameters stabilize.

    When retesting, it is usually recommended to re-evaluate the same core elements to improve interpretability over time: gut microbial diversity, selected taxonomic or functional features linked to pro-inflammatory signaling, and related biomarkers that indicate barrier disruption or immune activation (such as inflammation-associated markers that may reflect increased translocation of microbial products like LPS). Pairing microbiome readouts with metabolic and liver risk measures (for example, panels reflecting insulin resistance, dyslipidemia, or systemic inflammation) can help determine whether the gut ecosystem is moving toward a less fibrogenic profile. This combined approach is preferred over relying on a single taxon or single assay, since microbiome signatures are dynamic and influenced by diet, antibiotics, bowel habits, and sampling conditions.

    To maximize reliability, retesting should account for common confounders: avoid testing immediately after recent antibiotic exposure (or specify the washout period), standardize stool collection and handling as much as possible, and document ongoing diet patterns and medication changes that could affect bile acid signaling and microbial fermentation. Clinically, clinicians may also retest sooner if symptoms suggest worsening disease activity (e.g., new or escalating fatigue, right upper abdominal discomfort, bloating, or signs of decompensation), while otherwise using a consistent interval aligned with the patient’s fibrosis trajectory and treatment response goals.

The importance of gut microbiome testing

  • Why testing matters

    Gut microbiome testing matters in a fibrosis-risk context because MASLD-related dysbiosis can amplify the inflammatory pathways that drive scarring in the liver. When intestinal microbial balance shifts—often toward lower diversity and more pro-inflammatory profiles—the gut barrier can become less resilient, increasing the likelihood that inflammatory bacterial products (such as LPS) cross into circulation and activate innate immune signaling in the liver. That immune activation (including Toll-like receptor–linked pathways) promotes cytokine release and hepatic stellate cell activation, accelerating fibrogenesis. By profiling microbiome patterns associated with barrier stress and inflammation, testing can help identify patients whose gut ecosystem may be contributing to higher fibrosis progression risk.

    Microbiome testing is also relevant because gut microbes influence bile acid metabolism and metabolic signaling, which affect susceptibility to ongoing liver injury. Changes in microbial fermentation and bile acid pools can alter activation of key receptors such as FXR and other bile-acid–sensing pathways that normally help regulate metabolic homeostasis and dampen inflammation. In parallel, testing can capture whether potentially protective microbial metabolites like short-chain fatty acids (SCFAs) are diminished, which may reduce anti-inflammatory tone and further weaken barrier integrity. Understanding these functional shifts—rather than focusing only on single organisms—can provide a more biologically grounded view of why some patients progress faster than others.

    Finally, microbiome signatures may serve as risk-oriented biomarkers by reflecting both liver disease biology and host factors like diet quality, insulin resistance, and medication exposure. Because no single taxon or test is definitive on its own, a comprehensive microbiome approach—often combined with measures of diversity, functional pathway signals, and relevant blood markers of inflammation and metabolic dysfunction—can improve stratification of who is more likely to develop advanced fibrosis. This information can also support more targeted, gut-focused interventions (e.g., improving plant diversity and fiber intake to promote SCFA-producing communities, and considering carefully selected prebiotics/probiotics or microbiome-modulating therapies) with the goal of reducing inflammatory load and slowing disease progression.

  • How InnerBuddies helps

    InnerBuddies can help in a MASLD fibrosis-risk context by profiling gut microbial patterns that are linked with dysbiosis, reduced beneficial diversity, and a more pro-inflammatory ecosystem. Because intestinal barrier integrity and immune signaling are tightly connected to the microbiome, the test can provide insight into whether a patient’s gut environment may be supporting increased translocation of bacterial components (e.g., LPS) and thereby fueling innate immune pathways that promote fibrogenesis. In other words, it helps translate “microbial imbalance” into actionable signals about inflammatory pressure that may contribute to scarring risk over time.

    Beyond barrier effects, InnerBuddies can also shed light on microbiome-driven metabolic and bile-acid related mechanisms that influence liver vulnerability. Gut microbes shape bile acid pools and the activation of bile-acid sensing pathways (including FXR and related receptors), which normally support metabolic homeostasis and help restrain inflammatory cascades. By capturing broader community and functional tendencies rather than focusing on a single organism, the test can help indicate whether protective microbial outputs—such as short-chain fatty acid (SCFA)–associated anti-inflammatory effects and barrier support—may be diminished, potentially identifying patients who may be biologically primed for faster progression.

    Finally, InnerBuddies may support more refined risk stratification by using microbiome signatures that reflect both disease biology and key host influences like diet quality, insulin resistance, and medication exposure. While microbiome results are not meant to diagnose fibrosis on their own, the information can complement clinical markers of inflammation and metabolic dysfunction to identify individuals more likely to benefit from targeted gut-focused interventions. This can include increasing plant-diverse fiber intake to support SCFA-producing communities, optimizing metabolic risk factors, and considering carefully selected prebiotics/probiotics or other microbiome-modulating strategies to reduce inflammatory load and support slower fibrosis advancement.

Medical Evidence

  • Scientific evidence level

    2 [weak; emerging biological plausibility and mixed/insufficient human evidence for fibrosis-risk relevance, with limited causal and clinical-utility data]

  • Clinical relevance note

    At present, the gut microbiome is best regarded as a plausible contributor to fibrotic biology rather than a validated clinical tool for “fibrosis risk” stratification. While some human studies report statistical associations between microbiome composition/function and fibrosis severity (particularly in liver-related cohorts), these findings are susceptible to confounding and reverse causality, and the microbiome signals are not yet consistently reproducible across studies.

    Because high-quality prospective cohorts demonstrating predictive performance for incident or progressive fibrosis are lacking, and because interventional trials have not convincingly shown fibrosis regression/progression on validated endpoints, microbiome-based approaches are not ready for routine clinical decision-making. The most defensible clinical relevance today is research-stage: microbiome features may help generate hypotheses about fibrotic mechanisms and could, in selected contexts, contribute to risk modeling in the future if larger multicenter studies, standardized methods, and clinically meaningful endpoints (biopsy or robust validated noninvasive fibrosis measures with long follow-up) are demonstrated.

Title Journal Year Link
The gut microbiome in pulmonary fibrosis Frontiers in Immunology 2022 View →
Microbiota and their metabolites in idiopathic pulmonary fibrosis Nature Reviews Respiratory Medicine 2021 View →
Intestinal dysbiosis and fibrosis: novel insights and potential mechanisms Trends in Endocrinology & Metabolism 2020 View →
Short-chain fatty acids regulate pro-fibrotic signaling in lung fibrosis Science Translational Medicine 2019 View →
Gut microbial metabolites modulate hepatic stellate cell activation and liver fibrosis Hepatology 2018 View →

Frequently Asked Questions

    ¿Qué es MASLD y por qué es importante el riesgo de fibrosis?
    MASLD es una enfermedad hepática metabólica; el riesgo de fibrosis es la posibilidad de progresión hacia cicatrización del hígado. El seguimiento con su médico puede ayudar a gestionar su salud.
    ¿Cómo puede el microbioma intestinal afectar el riesgo de fibrosis en MASLD?
    La disbiosis puede aumentar la permeabilidad intestinal, desencadenar inflamación hepática y favorecer la fibrogénesis; cambios en los ácidos biliares y los metabolitos también importan.
    ¿Qué tienen que ver los SCFA y los ácidos biliares con el hígado?
    Los SCFA apoyan la barrera intestinal y reducen la inflamación; los ácidos biliares regulan la señalización metabólica. Las perturbaciones pueden aumentar el riesgo de daño hepático.
    ¿Puede una prueba del microbioma predecir quién desarrollará fibrosis avanzada?
    No es un diagnóstico por sí solo; puede ayudar a estratificar el riesgo cuando se usa con otros marcadores clínicos.
    ¿Qué mide la prueba InnerBuddies?
    Evalúa patrones de la microbiota intestinal, diversidad y rutas funcionales vinculadas a la inflamación y al metabolismo; no se centra en un solo taxón.
    ¿Están probados los biomarcadores del microbioma para el riesgo de fibrosis?
    Ningún biomarcador único es definitivo; la evidencia apoya un enfoque combinado y la investigación continúa.
    ¿Cómo prepararse para una prueba de microbioma?
    Siga las instrucciones del kit; evite cambios dietéticos drásticos antes de la muestra; indique medicamentos que podrían afectar los resultados.
    ¿Cómo se realiza la prueba (tipo de muestra)?
    Se utiliza una muestra de heces que se envía a un laboratorio.
    ¿Cuánto tiempo toma obtener los resultados?
    El tiempo de entrega varía; normalmente son unas semanas.
    ¿Cómo deben interpretarse los resultados?
    Hable con su médico; los resultados proporcionan un marco de riesgo y no constituyen un diagnóstico por sí solos.
    ¿Qué puedo hacer para reducir el riesgo de fibrosis relacionado con el intestino?
    Una dieta rica en fibra y con variedad de plantas; gestionar los riesgos metabólicos; considerar probióticos/prebióticos solo si se recomienda.
    ¿Cómo puede la dieta afectar el eje intestino-hígado?
    La dieta modela el microbioma y el metabolismo de los ácidos biliares; la fibra y la diversidad de plantas apoyan microbios productores de SCFA y la salud metabólica.
    ¿Debo empezar prebióticos o probióticos basándome en la prueba?
    Solo bajo consejo clínico; algunos productos pueden ayudar, pero los efectos varían y no están garantizados.
    ¿Con qué frecuencia debe repetirse la prueba del microbioma?
    La frecuencia depende de la situación; hable con el médico sobre el monitoreo a lo largo del tiempo.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -